Cell Proliferation Measured by Ki67 Staining and Correlation to Clinicopathological Parameters in Operable Breast Carcinomas from Vietnamese and Swedish Patients

• Vu Hong Thang

  Dept. of Oncology, Hanoi Medical University, Vietnam

• Lambert Skoog

  Dept. of Clinical Pathology and Cytology, Karolinska University Hospital, Solna, Stockholm, Sweden

• Nguyen Ba Duc

  Dept. of Oncology, Hanoi Medical University, Vietnam

• Ta Thanh Van

  Dept. of Biochemistry, Hanoi Medical University, Vietnam

• Edneia Tani

  Dept. of Clinical Pathology and Cytology, Karolinska University Hospital, Solna, Stockholm, Sweden

 Background: Cell proliferation measured by Ki67 has recently been shown to be a prognostic and predictive factor in breast cancer. The aim of this study was to compare cell proliferation determined by Ki67 expression with different clinicopathologic parameters among Vietnamese and Swedish women with breast cancer.

Materials and Methods:The study was based on series of breast cancer from Vietnamese patients treated in the National Cancer Hospital in Hanoi, Vietnam and from Swedish patients treated in the Karolinska Hospital, Stockholm, Sweden. Cell proliferation was measured by Ki67 staining in an automated procedure and was expressed as percentage of stained tumor cell nuclei.

Results:The distribution and mean of Ki67 indices from Vietnamese patients were similar to those estimated from Swedish patients, 27.7% (±17.1%) vs. 26.9% (±23.1%). There were no differences between the two series of patients with respect to proliferation index and age, tumor size and lymph node status. The mean Ki67 indices were higher in high grade tumors in both series. In addition, Swedish patients had significantly higher Ki67 indices in tumors associated with other poor prognostic factors as compared to Vietnamese, 52.8% vs. 31.9% in ER(-) tumors, 39.6% vs. 30.7% in PgR(-) tumors and 40.1% vs. 28.3% in HER2 amplified tumors, respectively.

Conclusions: The cell proliferation index in breast cancers was similar in the Vietnamese and Swedish series. High proliferation was associated with poor prognostic factors such as high grade, hormone receptor negativity and HER2amplification.

Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25(33): 5287-312. http://dx.doi.org/10.1200/JCO.2007.14.2364

Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 2010; 17(4): R245-62. http://dx.doi.org/10.1677/ERC-10-0136

Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006; 8(6): 216. http://dx.doi.org/10.1186/bcr1618

Wiesner FG, Magener A, Fasching PA, et al. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 2009; 18(2): 135-41. http://dx.doi.org/10.1016/j.breast.2009.02.009

Park D, Karesen R, Noren T, Sauer T. Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Arch 2007; 451(1): 11-8. http://dx.doi.org/10.1007/s00428-007-0435-2

Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 1997; 74(4): 433-7. http://dx.doi.org/10.1002/(SICI)1097-0215(19970822)74:4<433::AID-IJC12>3.0.CO;2-A

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11(2): 174-83. http://dx.doi.org/10.1016/S1470-2045(09)70262-1

Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P, Ferno M. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 2010; 23(2): 251-9. http://dx.doi.org/10.1038/modpathol.2009.167

Billgren AM, Tani E, Liedberg A, Skoog L, Rutqvist LE. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res Treat 2002; 71(2): 161-70. http://dx.doi.org/10.1023/A:1013899614656

Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 2006; 48(6): 674-82. http://dx.doi.org/10.1111/j.1365-2559.2006.02402.x

Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008; 17(4): 323-34. http://dx.doi.org/10.1016/j.breast.2008.02.002

Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer 2010; 17(4): 269-75. http://dx.doi.org/10.1007/s12282-009-0161-5

von Minckwitz G, Sinn HP, Raab G, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008; 10(2): R30. http://dx.doi.org/10.1186/bcr1989

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20(8): 1319-29. http://dx.doi.org/10.1093/annonc/mdp322

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22(8): 1736-47. http://dx.doi.org/10.1093/annonc/mdr304

Yamashita H, Nishio M, Toyama T, et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004; 6(1): R24-30. http://dx.doi.org/10.1186/bcr738

Nishimura. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Experimental and Therapeutic Medicine 2010; 1(5).

Zhang R, Chen HJ, Wei B, et al. Reproducibility of the Nottingham modification of the Scarff-Bloom-Richardson histological grading system and the complementary value of Ki-67 to this system. Chin Med J (Engl) 2010; 123(15): 1976-82.

Karanikas G, Koronakis N, Lagoudianakis EE, Grosomanidis D, Karavitis G, Koukoutsis I, et al. The value of proliferation indexes in breast cancer. Eur J Gynaecol Oncol 2010; 31(2): 181-4.

Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007; 110(4): 876-84. http://dx.doi.org/10.1002/cncr.22836

Thang VH, Tani E, Johansson H, et al. Difference in hormone receptor content in breast cancers from Vietnamese and Swedish women. Acta Oncol 2011; 50(3): 353-9. http://dx.doi.org/10.3109/0284186X.2010.528791

Thang VH, Tani E, Van TT, Krawiec K, Skoog L. HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH). Acta Oncol 2011; 50(3): 360-6. http://dx.doi.org/10.3109/0284186X.2010.547217

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19(5): 403-10. http://dx.doi.org/10.1111/j.1365-2559.1991.tb00229.x

Martinez-Arribas F, Martin-Garabato E, Lafuente P, et al. Proliferation measurement in breast cancer by two different methods. Anticancer Res 2006; 26(1A): 199-202.

Park S, Koo JS, Kim MS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2011.

• PDF